Sol-Gel Technologies Ltd. (SLGL) Company Overview

Sol-Gel Technologies Ltd. is an Israel-based specialty dermatology company listed on the Nasdaq Capital Market under ticker SLGL. It is not a diversified pharmaceutical manufacturer. Its present identity is a compact research organization built around rare and serious skin disease, with one pivotal clinical asset, one early-stage topical platform, and two FDA-approved products that are commercialized through partners. The company’s 2025 Form 20-F reports 28 employees at December 31, 2025, all located in Israel, illustrating how much of the operating model depends on external clinical sites, manufacturers, regulatory advisers, and commercial licensees.

Which pipeline assets define the company?

Why do the approved products still matter?

TWYNEO combines tretinoin and benzoyl peroxide using separate microencapsulation to solve a stability problem, while EPSOLAY uses encapsulated benzoyl peroxide to improve topical tolerability. The company’s official products page describes TWYNEO as the first FDA-approved fixed-dose tretinoin/BPO combination and EPSOLAY as the first FDA-approved BPO cream for inflammatory rosacea lesions. Strategically, these products validate Sol-Gel’s formulation capability and provide non-dilutive cash possibilities, but they are no longer the central operating focus. The company’s research value now depends primarily on whether SGT-610 can become the first approved therapy specifically for Gorlin syndrome.

Sol-Gel’s reported revenue is episodic rather than subscription-like. Cash receipts can arise from the sale or license of intellectual property, regulatory and commercial milestones, support services, and royalties on partner sales. That makes one quarter’s revenue a poor proxy for the underlying clinical value of the pipeline. In FY2025, the company generated $19.4 million of revenue, but $16.0 million came from the April 2025 sale and exclusive license of U.S. TWYNEO and EPSOLAY rights to Mayne Pharma. The transaction converted uncertain future U.S. royalties into two installments—$10.0 million received in Q2 2025 and $6.0 million received in Q4 2025.

What are the main revenue streams?

What does the FY2025 revenue mix reveal?

International agreements add optionality. The 2025 annual report disclosed up to $11.0 million of combined Canadian upfront and milestone potential from Searchlight, with low-double-digit to high-teen royalties, and up to $15.0 million of consideration from Beimei for China, Hong Kong, Macau, Taiwan, and Israel, including up to $5.0 million of royalties. In the Q1 2026 results, management said agreements signed across 2024–2026 could provide up to another $4.5 million of upfront and regulatory milestones and potentially support annual royalties of about $10.0 million by 2031. These are management forecasts, not contracted annual revenue.

The newest official reporting period is the quarter ended March 31, 2026. Q1 2026 revenue was only $0.108 million, down from $1.031 million in Q1 2025 because the comparison period included a Searchlight milestone. The more informative signal was spending: Q1 2026 R&D fell to $2.786 million from $8.843 million in Q1 2025, while Q1 2026 G&A was $1.177 million versus $1.257 million in Q1 2025. The resulting Q1 2026 operating loss narrowed to $3.855 million, and net loss narrowed to $3.727 million, or $1.31 per diluted share.

Why did quarterly R&D fall so sharply?

How much liquidity did the March 2026 offering add?

Sol-Gel sold 459,112 ordinary shares at $72.00 per share in March 2026, raising approximately $33.1 million of gross proceeds. At March 31, 2026, cash, cash equivalents, and deposits were $10.136 million, while marketable securities were $42.692 million. Total current assets were $55.789 million and current liabilities were $6.313 million, leaving a large current-liquidity buffer for a company with no reported bank debt. Management estimated that the March 31, 2026 liquidity pool could fund requirements into Q1 2028.

Sol-Gel’s history is best understood as a sequence of portfolio refinements. The company began as a formulation platform, proved that platform through two approvals, monetized or partnered assets that required commercial scale, and concentrated the resulting organization around rare dermatology. That is a materially different model from the earlier ambition to participate broadly in branded and generic topical products.

How did a formulation company become a rare-disease developer?

1. 1997
   Sol-Gel was incorporated in Israel. Its enduring capability became silica-based microencapsulation and topical formulation.
2. 2021
   TWYNEO received FDA approval in July 2021, validating the separate encapsulation of tretinoin and benzoyl peroxide. Sol-Gel also licensed U.S. TWYNEO and EPSOLAY commercialization to Galderma.
3. 2022
   EPSOLAY reached the U.S. market, proving a second differentiated topical product and establishing a royalty-based commercial model.
4. 2023
   Sol-Gel acquired patidegib rights from PellePharm for $4.0M upfront in January 2023 and began Phase 3 screening for SGT-610 in November 2023.
5. 2024
   The company sold and licensed selected TWYNEO rights to Beimei and expanded international commercialization agreements, shifting commercial execution to regional partners.
6. 2025
   Mayne Pharma purchased and licensed U.S. TWYNEO and EPSOLAY rights for $16.0M; Sol-Gel completed a 1-for-10 reverse share split and finished screening 184 Phase 3 patients, randomizing 113 at 41 sites.
7. 2026
   A $33.1M gross financing funded the SGT-610 readout and pre-commercial work; a U.S. patent notice of allowance extended key method-of-use protection to 2044; Sun Pharma added India to the TWYNEO partner map.

What did the 2025 U.S. product sale change?

The April 2025 Mayne transaction removed Sol-Gel from direct U.S. commercial exposure for TWYNEO and EPSOLAY. According to the official transaction announcement, Mayne acquired the U.S. rights after Sol-Gel and Galderma mutually terminated their prior arrangement. The strategic trade-off is clear: Sol-Gel sacrificed a portion of long-duration U.S. economics for near-term cash and a simpler cost structure. That decision made the company more concentrated, but it also aligned capital with SGT-610 rather than building a sales organization around mature acne and rosacea products.

SGT-610 is a topical 2% patidegib gel designed to inhibit the hedgehog signaling pathway in skin while avoiding the systemic adverse-event burden associated with chronic oral hedgehog inhibitors. The first target is adults with Gorlin syndrome, a rare inherited condition in which abnormal PTCH1 signaling leads patients to develop repeated basal cell carcinomas. The 2025 annual report estimates about 11,000 U.S. patients and notes that roughly 90% of people with the syndrome develop multiple BCCs by age 35. No therapy is specifically approved by the FDA or European Commission for Gorlin syndrome, so a successful preventive topical product could address a clearly defined unmet need.

What must the Phase 3 study prove?

The pivotal trial is multicenter, randomized, double-blind, and vehicle-controlled. Adults with confirmed PTCH1 mutations and at least 10 facial BCCs at screening receive either patidegib gel 2% or vehicle twice daily for 12 months. The study’s value is not determined by laboratory activity alone; it must demonstrate a clinically and statistically persuasive reduction in new lesions with acceptable local tolerability and adherence. Top-line results remain scheduled for Q4 2026. A positive result would support regulatory discussions and pre-commercial planning, while an equivocal or negative result would impair the principal asset before recurring royalties have scaled.

How do patents and indication expansion affect the opportunity?

The company’s pipeline page positions SGT-610 as the lead program and describes high-frequency BCC as the next potential indication. In May 2026, Sol-Gel received a notice of allowance for a U.S. method-of-use patent expected to protect topical patidegib therapy until 2044. The 2025 filing also described acquired patents potentially lasting to 2036, with possible extension to 2041, and additional applications that could extend protection further if granted. This layered patent estate matters because the company’s economic case depends on maintaining exclusivity long enough to recover clinical, manufacturing, and commercialization investment.

Sol-Gel does not possess a scale moat. Larger dermatology and oncology companies have deeper clinical, manufacturing, market-access, and sales resources. Its defensible assets are narrower: specialized topical formulation know-how, two prior NDA approvals, a late-stage rare-disease trial, orphan and breakthrough designations, partner relationships, and a patent estate around patidegib. These resources can be valuable under a VRIO-style analysis because they are relevant and relatively uncommon, but durability depends on clinical proof and enforceable exclusivity.

Where is the differentiation strongest?

The differentiation is clearest in SGT-610. Oral hedgehog inhibitors validate the biological pathway, but tolerability can constrain long-term use. A topical preventive therapy with limited systemic exposure could create a distinct clinical position. TWYNEO and EPSOLAY provide precedent: microencapsulation enabled a previously unstable tretinoin/BPO combination and made benzoyl peroxide usable in rosacea. However, formulation advantage must translate into efficacy, tolerability, manufacturing consistency, reimbursement, and physician adoption.

Which competitive forces matter most?

Sol-Gel’s balance sheet is stronger after the March 2026 offering, but the business is not economically self-funding. FY2025 revenue benefited from asset-sale accounting, and Q1 2026 returned to a very low revenue base. The company has no conventional product gross-margin profile because revenue is mainly licenses and royalties while operating costs are recorded primarily in R&D and G&A. For analysis, the most useful questions are how quickly clinical spending consumes liquidity, whether partner receipts offset burn, and whether the company can reach a regulatory or partnering milestone before another financing is required.

What does the annual financial trend show?

How should investors interpret cash flow?

FY2025 operating cash flow was positive $0.322 million, compared with cash use of $13.889 million in FY2024. That apparent improvement did not come from recurring profitability. It reflected the timing of Mayne and other partner cash receipts and working-capital movements against a FY2025 net loss of $6.127 million. FY2025 investing cash outflow was $8.580 million, mainly because Sol-Gel bought $14.078 million of marketable securities and received $5.511 million from maturities and sales. Property-and-equipment purchases were only $0.047 million in FY2025, confirming that capital intensity sits in clinical work, external manufacturing, and working capital rather than owned plants.

Ownership is concentrated. Moshe Arkin serves as executive chairman and interim chief executive officer, and his controlled entity M. Arkin Dermatology remains the dominant shareholder. This is a one-share, one-vote company, but one-share, one-vote does not imply dispersed control when one holder owns a majority. The practical consequence is that outside investors have limited influence over director elections, strategic transactions, financing decisions, and executive leadership.

How much control does Moshe Arkin have?

The most useful current control document is the April 2026 Schedule 13D amendment, which recalculated Mr. Arkin’s beneficial ownership after the offering. The financing diluted his reported stake from roughly 65% before the deal to 56.60% afterward, but it did not remove control. A separate Opaleye Schedule 13G amendment reported 500,000 shares, or 15.41%, at March 31, 2026.

What did the financing change in the investor base?

The March 2026 offering brought in healthcare-focused institutions including Great Point Partners, Trails Edge Capital Partners, Surveyor Capital, Affinity Asset Advisors, Squadron Capital Management, Stonepine Capital Management, and AuGC BioFund. Specialist participation can improve market validation and financing access, but it does not eliminate binary clinical risk. It also increases the importance of milestone timing: funds were raised specifically to carry SGT-610 through the Q4 2026 readout, pre-commercial activity, and general working capital. The company’s May 2025 1-for-10 reverse share split reduced outstanding shares from about 27.9 million to about 2.8 million before the 2026 offering; per-share historical figures in current filings are adjusted for that split.

For a development-stage dermatology company, conventional revenue growth and EBITDA multiples are secondary. The highest-value operating indicators are clinical enrollment and efficacy, regulatory status, patent duration, cash runway, R&D composition, partner launches, and dilution. A student or analyst should connect each KPI to a decision point rather than treating it as a dashboard statistic.

Which operating metrics should researchers track?

What could improve or weaken the story?

The risk profile is concentrated rather than diversified. Sol-Gel depends on a small number of assets, third-party trial sites and manufacturers, regulators, and licensees. The opportunity profile is equally concentrated: a successful SGT-610 readout, combined with 2044 patent protection and a feasible HF-BCC expansion, could transform the company from a milestone-funded developer into a rare-disease commercial or partnering platform.

A conventional DCF built from recent reported revenue would be misleading because FY2025 included a $16.0 million asset transaction and Q1 2026 revenue was only $0.108 million. A more defensible approach is a probability-adjusted sum of parts. The model should separate SGT-610 in Gorlin syndrome, potential HF-BCC expansion, SGT-210 option value, international TWYNEO/EPSOLAY milestones and royalties, cash and securities, contractual milestone obligations to PellePharm, and future dilution.

Which assumptions drive a DCF or rNPV model?

The company’s own peak-sales estimate for SGT-610 exceeds $600 million, but that figure is management’s scenario and depends on patient numbers, penetration, and annual pricing. A serious model should test much lower outcomes and explicitly subtract development milestones of up to $6.0 million, commercial milestones of up to $64.0 million—rising to $89.0 million above $500 million of sales—and tiered royalties owed under the PellePharm acquisition. It should also avoid assigning full value to HF-BCC before the Gorlin trial establishes proof of concept.